These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22716155)

  • 21. Cannabinoids in clinical practice.
    Williamson EM; Evans FJ
    Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.
    Hermann D; Schneider M
    Curr Pharm Des; 2012; 18(32):4897-905. PubMed ID: 22716143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis, cannabinoids, and health.
    Lafaye G; Karila L; Blecha L; Benyamina A
    Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.
    Stott C; White L; Wright S; Wilbraham D; Guy G
    Springerplus; 2013 Dec; 2(1):236. PubMed ID: 23750331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
    Sellers EM; Schoedel K; Bartlett C; Romach M; Russo EB; Stott CG; Wright S; White L; Duncombe P; Chen CF
    Clin Pharmacol Drug Dev; 2013 Jul; 2(3):285-94. PubMed ID: 27121791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of cannabinoids.
    Grotenhermen F
    Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabis-induced psychosis associated with high potency "wax dabs".
    Pierre JM; Gandal M; Son M
    Schizophr Res; 2016 Apr; 172(1-3):211-2. PubMed ID: 26876313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A selective review of medical cannabis in cancer pain management.
    Blake A; Wan BA; Malek L; DeAngelis C; Diaz P; Lao N; Chow E; O'Hearn S
    Ann Palliat Med; 2017 Dec; 6(Suppl 2):S215-S222. PubMed ID: 28866904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cannabis and cannabinoids as drugs].
    Khiabani HZ; Mørland J
    Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.
    D'Souza DC; Ranganathan M; Braley G; Gueorguieva R; Zimolo Z; Cooper T; Perry E; Krystal J
    Neuropsychopharmacology; 2008 Sep; 33(10):2505-16. PubMed ID: 18185500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of cannabis in supportive care and treatment of brain tumor.
    Likar R; Nahler G
    Neurooncol Pract; 2017 Sep; 4(3):151-160. PubMed ID: 31385997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
    Maccarrone M; Maldonado R; Casas M; Henze T; Centonze D
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):443-455. PubMed ID: 28276775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabinoids and Psychosis.
    D'Souza DC; Radhakrishnan R; Sherif M; Cortes-Briones J; Cahill J; Gupta S; Skosnik PD; Ranganathan M
    Curr Pharm Des; 2016; 22(42):6380-6391. PubMed ID: 27568729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.